Hydrazide containing nuclear transport modulators and uses thereof
The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
1. A method for treating a disorder associated with CRM1 activity comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the disorder is selected from a myelodysplastic syndrome or a myeloproliferative disorder.
3. The method according to claim 1 , wherein the disorder is a cancer selected from colon cancer, lung cancer or brain cancer.
4. The method according to claim 3 , wherein the compound is administered together with a second therapeutic useful for treating cancer.
5. The method according to claim 3 , wherein the cancer is brain cancer.
6. The method according to claim 3 , wherein the cancer is colon cancer.
7. The method according to claim 3 , wherein the cancer is lung cancer.
8. The method according to claim 1 , wherein the compound is administered together with a second therapeutic agent.
9. The method according to claim 2 , wherein the compound is administered together with a second therapeutic useful for treating cancer.
10. The method according to claim 1 , wherein the compound is administered orally.
11. The method according to claim 2 , wherein the compound is administered orally.
12. The method according to claim 3 , wherein the compound is administered orally.